# A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

> **NCT05198804** · PHASE1,PHASE2 · COMPLETED · sponsor: **K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc** · enrollment: 117 (actual)

## Conditions studied

- Ovarian Cancer
- Platinum-resistant Ovarian Cancer
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer

## Interventions

- **DRUG:** Azenosertib
- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT05198804
- **Lead sponsor:** K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-27
- **Primary completion:** 2025-10-15
- **Final completion:** 2026-01-19
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05198804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05198804, "A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05198804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*